MedTrace Logo

A Study of ELI-002 7P, With or Without Tislelizumab, in People With Pancreatic Cancer

NCT07671339 · Status: RECRUITING · Phase: PHASE1 · Type: INTERVENTIONAL · Enrollment: 20

Last updated 2026-06-26

No results posted yet for this study

Summary

The researchers are doing this study to find out whether ELI-002 7P in combination with mFOLFIRINOX, with or without tislelizumab, is a safe treatment approach in people who have pancreatic ductal adenocarcinoma (PDAC) with a KRAS mutation. In addition, the researchers are doing this study to find out whether the study treatment is effective against PDAC.

Conditions

Interventions

DRUG

ELI-002 7P

a subcutaneous (SC) injection under the skin

DRUG

Tislelizumab

s an intravenous (IV) infusion

DRUG

mFOLFIRINOX

neoadjuvant mFOLFIRINOX (5-Fluorouracil,oxaliplatin, leucovorin, irinotecan)

Sponsors & Collaborators

  • BeOne Medicines

    collaborator INDUSTRY

  • Breakthrough Cancer

    collaborator UNKNOWN

  • Elicio Therapeutics

    collaborator INDUSTRY

  • Lustgarten Foundation

    collaborator OTHER

  • Memorial Sloan Kettering Cancer Center

    lead OTHER

Principal Investigators

  • Kevin Soares, MD · Memorial Sloan Kettering Cancer Center

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
PARALLEL

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2026-06-22
Primary Completion
2028-06-30
Completion
2028-06-30
FDA Drug
Yes

Countries

  • United States

Study Locations

More Related Trials

Entities

Drugs
Diseases
Companies

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT07671339 on ClinicalTrials.gov